Patents by Inventor Jonathan Oliner

Jonathan Oliner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR DETECTING MUTANT P53 FUNCTION
    Publication number: 20210405056
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The methods described herein can detect and quantify the ability of a therapeutic agent to reconform a mutant conformation of mutant p53 to a conformation that possesses physiological activity of wild type p53. The disclosed method can be used as a companion diagnostic to detect and quantify the efficacy of a therapeutic agent in reducing the progression of cancers that contain a p53 mutation.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 30, 2021
    Inventors: Arnold LEVINE, Jonathan OLINER, Thomas W. DAVIS, Mary Kate McBRAYER
  • Angiopoietin-2 specific binding agents
    Patent number: 7658924
    Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: February 9, 2010
    Assignee: Amgen Inc.
    Inventors: Jonathan Oliner, Kevin Graham
  • Ang2 and Vegf Inhibitor Combinations
    Publication number: 20090304694
    Abstract: The invention provides methods for using Ang2 inhibitors in combination with VEGF inhibitors to treat disease. The invention also provides compositions, kits, formulations, and specific disease treatments relating thereto.
    Type: Application
    Filed: January 19, 2007
    Publication date: December 10, 2009
    Applicant: AMGEN INC.
    Inventors: Jonathan Oliner, Richard Kendall, Rakesh Kumar
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Publication number: 20070225221
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: August 4, 2006
    Publication date: September 27, 2007
    Applicant: AMGEN INC.
    Inventors: Jonathan Oliner, Hosung Min
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Publication number: 20070093418
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: August 4, 2006
    Publication date: April 26, 2007
    Applicant: AMGEN INC.
    Inventors: Jonathan Oliner, Hosung Min
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Publication number: 20070093419
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: August 4, 2006
    Publication date: April 26, 2007
    Applicant: AMGEN INC.
    Inventors: Jonathan Oliner, Hosung Min
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Publication number: 20070072801
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: August 4, 2006
    Publication date: March 29, 2007
    Applicant: AMGEN INC.
    Inventors: Jonathan Oliner, Hosung Min
  • Specific binding agents of human angiopoietin-2
    Publication number: 20060122370
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: January 30, 2006
    Publication date: June 8, 2006
    Inventors: Jonathan Oliner, Hosung Min
  • Angiopoietin-2 specific binding agents
    Publication number: 20060018909
    Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.
    Type: Application
    Filed: November 4, 2004
    Publication date: January 26, 2006
    Inventors: Jonathan Oliner, Kevin Graham
  • Determining signal transduction pathways
    Publication number: 20050019797
    Abstract: Experimental and analytical methods enable reconstruction of signal transduction networks from gene expression profiles. Signal transduction pathways can be reverse-engineered by 1) experimentally manipulating individual genes, 2) generating cellular expression profiles, and 3) analyzing for common patterns among these profiles. Analysis of patterns among profiles permits reconstruction of pathways and networks of interrelationships among genes and their products.
    Type: Application
    Filed: May 28, 2004
    Publication date: January 27, 2005
    Applicant: Affymetrix, Inc.
    Inventors: Jonathan Oliner, Earl Hubbell
  • Expression monitoring of downstream genes in the BRCA1 pathway
    Publication number: 20010051339
    Abstract: Analysis of the genes whose expression is affected by BRCA1 has identified a set of genes, each of which is up- or down-regulated by BRCA1. Each of these genes, alone or in groups, can be used to determine the mutational status of a BRCA1 gene, to determine whether a particular allelic variant affects BRCA1 function, to diagnose neoplasia, and to help identify candidate drugs which may be useful as anti-neoplastic agents.
    Type: Application
    Filed: March 15, 2001
    Publication date: December 13, 2001
    Inventors: Jonathan Oliner, Fred Christians, Vivi Truong, Daniel Haber, James Bean, David Miklos, Denis Paul Harkin
  • Expression monitoring of downstream genes in the BRCA1 pathway
    Patent number: 6258536
    Abstract: Analysis of the genes whose expression is affected by BRCA1 has identified a set of genes, each of which is up- or down-regulated by BRCA1. Each of these genes, alone or in groups, can be used to determine the mutational status of a BRCA1 gene, to determine whether a particular allelic variant affects BRCA1 function, to diagnose neoplasia, and to help identify candidate drugs which may be useful as anti-neoplastic agents.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: July 10, 2001
    Inventors: Jonathan Oliner, Fred Christians, Vivi Truong, Daniel Haber, James Bean, David Miklos, Denis Paul Harkin
  • Downstream genes of tumor suppressor WT1
    Patent number: 6177248
    Abstract: Methods are provided for diagnosing cancers, drug-screening, and functionally analyzing mutations involving the WT1 gene. The methods involve use of the newly identified set of genes which are regulated by WT1 as well as by the set of genes which are regulated by WT1 fusions to EWS. Monitoring expression levels of these sets of genes can be used as an indicator of the genetic status of the gene. It can also identify which have similar effects on down-stream genes.
    Type: Grant
    Filed: February 24, 1999
    Date of Patent: January 23, 2001
    Assignee: Affymetrix, Inc.
    Inventors: Jonathan Oliner, Vivi Truong, Daniel Haber, Sean Lee